Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Dermatologic 2Sarcoma 1Head & Neck 1Breast 1

Conditions

Carcinoma, Merkel Cell 3Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Carcinoma, Squamous Cell 2Carcinoma, Basal Cell 2Sezary Syndrome 1Sarcoma 1Paget Disease, Extramammary 1Muir-Torre Syndrome 1Microcystic adnexal carcinoma 1Melanoma 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Eccrine Porocarcinoma 1Carcinoma, Signet Ring Cell 1Carcinoma, Basosquamous 1Breast Neoplasms 1Adenocarcinoma, Papillary 1

Interventions

pembrolizumab 3talimogene laherparepvec 2spartalizumab 1fludarabine 1atezolizumab 1aldesleukin 1TTI-621 1Radiation 1RXDX-106 1Proton Pump Inhibitors 1Nivolumab 1Ipilimumab 1Interleukin-2 1Injections, Subcutaneous 1In Situ Hybridization, Fluorescence 1Hydrocortisone 1Gemcitabine 1Cyclophosphamide 1Carboxylesterase 1Antineoplastic Protocols 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Squamous Cell × talimogene laherparepvec × Lymphoid × Clear all
NCT02890368 2023-04-05

Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides

Pfizer

Phase 1 Terminated
56 enrolled
BreastDermatologicLymphoidSarcoma

Breast Neoplasms, Carcinoma, Squamous Cell, Melanoma, Mycosis Fungoides, Sarcoma, Carcinoma, Merkel Cell

NCT03458117 2022-03-18

20139157 T-VEC

University of Zurich

Phase 1 Completed
26 enrolled
DermatologicLymphoid

Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡